Literature DB >> 7803253

CD45 isoform expression on human haemopoietic cells at different stages of development.

W Craig1, S Poppema, M T Little, W Dragowska, P M Lansdorp.   

Abstract

Alternate splicing and glycosylation produce multiple CD45 isoforms which are selectively expressed on the surface of cells of the haemopoietic system. The expression of CD45RA, CD45RB and CD45RO on CD34+ and CD34- haemopoietic cells from umbilical cord blood, bone marrow and fetal liver were studied by flow cytometry. CD34+ subpopulations defined by CD45 isoform expression were sorted from bone marrow and tested in long-term culture assays. By combining results of functional studies with phenotypic data and previously published information, the following pattern of CD45 isoform expression on early haemopoietic cells was established. The most primitive CD34+ cells are CD45RO+ CD45RB+ and express low or undetectable levels of CD45RA. Upon erythroid differentiation, CD34+ cells remain CD45RO+ CD45RB+, whereas commitment into the myeloid and lymphoid lineages coincides with down-regulation of CD45RO and up-regulation of CD45RA. As a result, the majority of CD34+ cells can be divided into two mutually exclusive populations of cells which express either CD45RO or CD45RA. This notion was confirmed in this study by three-colour immunofluorescence. The alternative expression of various CD45 isoforms on functionally distinct haemopoietic cells suggests an important role for these molecules in the proliferation and differentiation of haemopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803253     DOI: 10.1111/j.1365-2141.1994.tb04972.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells.

Authors:  Shannon L McKinney-Freeman; Olaia Naveiras; Frank Yates; Sabine Loewer; Marsha Philitas; Matthew Curran; Peter J Park; George Q Daley
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

2.  Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice.

Authors:  Christopher J Hogan; Elizabeth J Shpall; Gordon Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  The citrus flavanone naringenin attenuates zymosan-induced mouse joint inflammation: induction of Nrf2 expression in recruited CD45+ hematopoietic cells.

Authors:  Allan J C Bussmann; Sergio M Borghi; Tiago H Zaninelli; Telma S Dos Santos; Carla F S Guazelli; Victor Fattori; Talita P Domiciano; Felipe A Pinho-Ribeiro; Kenji W Ruiz-Miyazawa; Antonio M B Casella; Josiane A Vignoli; Doumit Camilios-Neto; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflammopharmacology       Date:  2019-01-05       Impact factor: 4.473

4.  Differential Expression of CD45RO and CD45RA in Bovine T Cells.

Authors:  Anmol Kandel; Lei Li; Akanksha Hada; Zhengguo Xiao
Journal:  Cells       Date:  2022-06-04       Impact factor: 7.666

5.  Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury.

Authors:  Hadar Arien-Zakay; Galit Gincberg; Arnon Nagler; Gadi Cohen; Sigal Liraz-Zaltsman; Victoria Trembovler; Alexander G Alexandrovich; Ilan Matok; Hanan Galski; Uriel Elchalal; Peter I Lelkes; Philip Lazarovici; Esther Shohami
Journal:  J Neurotrauma       Date:  2014-07-14       Impact factor: 5.269

6.  Insulin-like growth factor I promotes cord blood T cell maturation through monocytes and inhibits their apoptosis in part through interleukin-6.

Authors:  Helen K W Law; Wenwei Tu; Enmei Liu; Yu Lung Lau
Journal:  BMC Immunol       Date:  2008-12-17       Impact factor: 3.615

7.  Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome.

Authors:  Omri Teltsh; Angel Porgador; Eitan Rubin
Journal:  Oncotarget       Date:  2015-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.